Filtered By:
Condition: Thrombosis
Drug: Warfarin

This page shows you your search results in order of relevance. This is page number 17.

Order by Relevance | Date

Total 1175 results found since Jan 2013.

Fatal stroke following treatment with apixaban in a patient with atrial fibrillation and left atrial appendage thrombus
Atrial fibrillation increases the risk of ischemic stroke 4–5 fold [1] and doubles the mortality independently of other vascular risk factors [2]. The vast majority (>90%) of thrombi associated with atrial fibrillation originate from the left atrial appendage [3]. The direct factor Xa inhibitor apixaban is superior to warfarin in terms of stroke prevention with a lower risk of bleeding and mortality [4].
Source: International Journal of Cardiology - March 23, 2016 Category: Cardiology Authors: Ashkan Eftekhari, Dorte Damgaard, Erik L. Grove Tags: Correspondence Source Type: research

Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation
This article reviews and highlights real and perceived implications of VKAs for the prevention of stroke in patients with non-valvular AF, with specific reference to their strengths and weaknesses compared with DOACs.
Source: Journal of Thrombosis and Thrombolysis - November 27, 2016 Category: Hematology Source Type: research

Edoxaban for stroke prevention in atrial fibrillation and treatment of venous thromboembolism: an expert position paper.
Abstract Edoxaban is the most recent available representative of the Non-Vitamin K antagonist oral anticoagulants (NOAC). The approval was based on the largest phase III trials of NOACs for stroke prevention in patients with non-valvular atrial fibrillation (AF, ENGAGE-AF), and for the treatment of venous thromboembolism (VTE, HOKUSAI-VTE). In both trials, edoxaban was associated with similar efficacy and a significant reduction in bleeding events with respect to the pre-defined primary safety endpoints, as compared to warfarin.Additionally, the once daily dosing of edoxaban, the clinically investigated strateg...
Source: Hamostaseologie - February 23, 2017 Category: Hematology Authors: Weiss TW, Rohla M, Dieplinger B, Domanovits H, Fries D, Vosko MR, Gary T, Ay C Tags: Wien Med Wochenschr Source Type: research

Re-initiation of oral-anticoagulants in survivors of hemorrhagic stroke
Publication date: Available online 22 May 2017 Source:Apollo Medicine Author(s): Pushpendra Nath Renjen, Dinesh Chaudhari Intra-cerebral hemorrhage (ICH) is the most feared and the deadliest complication of oral anticoagulant therapy, i.e. warfarin (Coumadin). After such an occurrence, clinicians wonder whether their patients should resume anticoagulant therapy. The decisions to reverse and re-initiate anticoagulation hinge on the phase of stroke as the risk of thromboembolism outweighs risk of bleeding in the chronic phase. Hence in the short term, most patients with ICH will benefit from acute reversal of anticoagulatio...
Source: Apollo Medicine - July 21, 2017 Category: General Medicine Source Type: research

Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (From the Edoxaban Versus Warfarin in Subjects Undergoing Cardioversion of Atrial Fibrillation ENSURE-AF Study)
In the ENSURE-AF study, edoxaban was compared to enoxaparin –warfarin in patients undergoing electrical cardioversion of nonvalvular atrial fibrillation, showing comparable low rates of bleeding and thromboembolism. This ancillary analysis investigated differences in relation to stroke and bleeding risk profiles. Secondly, we determined clinical risk profi les to quality of anticoagulation control in the warfarin arm. Primary efficacy (composite of stroke, systemic embolic event, myocardial infarction, and cardiovascular death) and safety (composite of major and clinically relevant nonmajor bleeding) outcomes and time to...
Source: The American Journal of Cardiology - October 26, 2017 Category: Cardiology Authors: Gregory Y.H. Lip, Jose L. Merino, G. Andrei Dan, Sakis Themistoclakis, Kenneth A. Ellenbogen, Raffaele De Caterina, Assen Goudev, James Jin, Michael Melino, Shannon M. Winters, Andreas Goette Source Type: research

Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after PCI: An ancillary analysis from the RE-DUAL PCI trial
ConclusionDabigatran dual therapy reduced bleeding events irrespective of bleeding risk category and demonstrated similar efficacy regardless of stroke risk category when compared with warfarin triple therapy.
Source: American Heart Journal - March 4, 2019 Category: Cardiology Source Type: research

A Case of Ischemic Stroke With Congenital Protein C Deficiency and Carotid Web Successfully Treated by Anticoagulant and Carotid Stenting
Conclusion: To our knowledge, this is the first report in which an immediate thrombus formation on the carotid web was observed in a patient with congenital protein C deficiency. In a case of acute ischemic stroke with carotid web, especially when congenital coagulopathy such as protein C deficiency is suspected, careful follow-up with ultrasound imaging should be performed.
Source: Frontiers in Neurology - February 17, 2020 Category: Neurology Source Type: research

Is intravenous thrombolysis safe for acute ischemic stroke patients taking warfarin with INR 1.9?: A case report
Conclusion: The clinical guidelines are still the main reference for guiding clinical practice, and the main thrombolytic standards and contraindications for treatment still need to be conformed. On this basis, for individualized patients, clinicians must accurately judge the cause of acute stroke, to make optimal choice, reduce disability and mortality, and improve quality of life of patients.
Source: Medicine - March 1, 2020 Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research

AUGUSTUS: Apixaban Bests Warfarin Despite Prior Stroke AUGUSTUS: Apixaban Bests Warfarin Despite Prior Stroke
In a prespecified secondary analysis of patients with a history of stroke, TIA, or thromboembolism, apixaban maintained an advantage over warfarin.Medscape Medical News
Source: Medscape Cardiology Headlines - March 10, 2020 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news

Risk of stroke and other thromboembolic complications after interruption of DOAC therapy compared with warfarin therapy in patients with atrial fibrillation: a retrospective cohort analysis
This study did not find a significant difference in the complication rate after interruption of DOAC therapy compared with interruption of warfarin therapy in hospitalized patients with a high risk of thromboembolism.
Source: Journal of Investigative Medicine - November 25, 2021 Category: Research Authors: Hellerman Itzhaki, M., Greenberg, N., Margalit, I., Shochat, T., Krause, I., Goldberg, E. Tags: Original research Source Type: research

Ischemic stroke in the setting of supratherapeutic International Normalized Ratio following coronavirus disease 2019 infection: a case report
ConclusionsThis case report highlights the potential for thromboembolic events, including stroke, in patients with COVID-19 infection, even when receiving therapeutic anticoagulation therapy. Healthcare providers should be vigilant for signs of thrombosis in COVID-19 patients, particularly those with pre-existing risk factors. Further research is necessary to understand the pathophysiology and optimal management of thrombotic complications in COVID-19 patients.
Source: Journal of Medical Case Reports - May 31, 2023 Category: General Medicine Source Type: research

Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a rebuttal
New oral anticoagulant drugs (NOACs) have been made available for the treatment of thrombo‐embolism. Pengo et al. [1] reviewed the results of three such new agents approved by various authorities for stroke prevention in atrial fibrillation (AF). The three new NOACs were evaluated in multicentre comparisons of ”stroke” prevention in patients with AF against the established vitamin‐K antagonist (VKA) warfarin, in three US phase lll studies. © 2013 International Society on Thrombosis and Haemostasis
Source: Journal of Thrombosis and Haemostasis - February 11, 2013 Category: Hematology Authors: L. Poller, J. Jespersen, S. Ibrahim, A. Pattison, Tags: Letter ‐ Rebuttal Source Type: research

Mitral valve repair and bioprosthetic replacement without postoperative anticoagulation does not increase the risk of stroke or mortality ADULT CARDIAC
CONCLUSIONS Despite current guidelines recommending postoperative anticoagulation following MVRR or bioprosthetic replacement, the avoidance of warfarin does not increase perioperative complications and has no impact on intermediate survival. Accordingly, a prospective randomized study to adjudicate the role of extended warfarin thromboprophylaxis in mitral valve surgery is warranted.
Source: European Journal of Cardio-Thoracic Surgery - June 13, 2013 Category: Cardiovascular & Thoracic Surgery Authors: Schwann, T. A., Engoren, M., Bonnell, M., Clancy, C., Khouri, S., Kabour, A., Jamil, T., Habib, R. H. Tags: ADULT CARDIAC Source Type: research

Benefit of Warfarin Compared With Aspirin in Patients With Heart Failure in Sinus Rhythm: A Subgroup Analysis of WARCEF, a Randomized Controlled Trial Original Articles
Conclusions— In patients <60 years, warfarin improved outcomes over aspirin with or without inclusion of major hemorrhage. In patients ≥60 years, there was no treatment difference, but the aspirin group had significantly better outcomes when major hemorrhage was included. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00041938.
Source: Circulation: Heart Failure - September 17, 2013 Category: Cardiology Authors: Homma, S., Thompson, J. L. P., Sanford, A. R., Mann, D. L., Sacco, R. L., Levin, B., Pullicino, P. M., Freudenberger, R. S., Teerlink, J. R., Graham, S., Mohr, J. P., Massie, B. M., Labovitz, A. J., Di Tullio, M. R., Gabriel, A. P., Lip, G. Y. H., Estol, Tags: Congestive, Cerebrovascular disease/stroke, Thrombosis risk factors, Anticoagulants, Antiplatelets Original Articles Source Type: research

The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran
Dabigatran is an oral direct thrombin inhibitor (DTI) licensed for stroke prevention in atrial fibrillation and likely to be soon approved in Europe for treatment of venous thrombosis. Predictable pharmacokinetics and a reduced risk of intracranial haemorrhage do not negate the potential risk of haemorrhage. Unlike warfarin, there is no reversal agent and measurement of the anticoagulant effect is not ‘routine’. The prothrombin time/international normalised ratio response to dabigatran is inconsistent and should not be measured when assessing a patient who is bleeding or needs emergency surgery. The activated p...
Source: Emergency Medicine Journal - January 15, 2014 Category: Emergency Medicine Authors: Alikhan, R., Rayment, R., Keeling, D., Baglin, T., Benson, G., Green, L., Marshall, S., Patel, R., Pavord, S., Rose, P., Tait, C. Tags: Poisoning/Injestion, Open access, Drugs: cardiovascular system, Stroke, Poisoning Review Source Type: research